Apollon Wealth Management LLC Has $512,000 Stock Position in Centene Co. (NYSE:CNC)

Apollon Wealth Management LLC trimmed its holdings in Centene Co. (NYSE:CNC) by 5.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,802 shares of the company’s stock after selling 373 shares during the quarter. Apollon Wealth Management LLC’s holdings in Centene were worth $512,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Swedbank AB acquired a new stake in Centene in the 1st quarter worth $914,080,000. Boston Partners grew its position in Centene by 0.4% during the first quarter. Boston Partners now owns 8,652,177 shares of the company’s stock worth $678,033,000 after buying an additional 32,427 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Centene by 0.5% during the second quarter. Bank of New York Mellon Corp now owns 5,491,968 shares of the company’s stock valued at $364,117,000 after acquiring an additional 25,595 shares during the period. Capital International Investors raised its holdings in Centene by 60.2% in the 1st quarter. Capital International Investors now owns 5,216,486 shares of the company’s stock valued at $409,390,000 after acquiring an additional 1,959,460 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Centene by 14.2% during the 2nd quarter. Legal & General Group Plc now owns 5,113,759 shares of the company’s stock worth $339,042,000 after purchasing an additional 636,683 shares in the last quarter. Institutional investors and hedge funds own 93.63% of the company’s stock.

Centene Stock Down 2.1 %

Shares of NYSE CNC opened at $57.46 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.64. The company has a market cap of $29.01 billion, a price-to-earnings ratio of 9.98, a price-to-earnings-growth ratio of 0.80 and a beta of 0.49. Centene Co. has a 12-month low of $57.25 and a 12-month high of $81.42. The firm’s 50-day simple moving average is $68.06 and its 200 day simple moving average is $71.01.

Insider Transactions at Centene

In related news, CEO Sarah London purchased 4,117 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were bought at an average price of $60.80 per share, with a total value of $250,313.60. Following the purchase, the chief executive officer now directly owns 667,229 shares in the company, valued at $40,567,523.20. This trade represents a 0.62 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CFO Andrew Lynn Asher acquired 17,200 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were bought at an average cost of $58.14 per share, with a total value of $1,000,008.00. Following the completion of the purchase, the chief financial officer now owns 486,847 shares of the company’s stock, valued at $28,305,284.58. This trade represents a 3.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.33% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Barclays reduced their target price on Centene from $97.00 to $91.00 and set an “overweight” rating for the company in a research report on Tuesday, October 29th. StockNews.com downgraded shares of Centene from a “strong-buy” rating to a “buy” rating in a report on Monday, October 28th. Jefferies Financial Group cut shares of Centene from a “buy” rating to a “hold” rating and lowered their target price for the company from $83.00 to $69.00 in a research note on Wednesday, July 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $90.00 price objective on shares of Centene in a report on Tuesday, October 1st. Finally, Oppenheimer dropped their target price on Centene from $110.00 to $95.00 and set an “outperform” rating for the company in a report on Monday, July 29th. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.92.

Centene Company Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.